

---

# Prevalence of Undiagnosed Monkeypox Virus Infections during Global Mpox Outbreak, United States, June–September 2022

Faisal S. Minhaj, Vijay Singh, Stephanie E. Cohen, Michael Townsend, Hyman Scott, John Szumowski, C. Bradley Hare, Pallavi Upadhyay, Jairus Reddy, Barbara Alexander, Nicolle Baird, Terese Navarra, Lalita Priyamvada, Nhien Wynn, William C. Carson, Solomon Odafe, Sarah Anne J. Guagliardo, Emily Sims, Agam K. Rao, Panayampalli S. Satheshkumar, Paul J. Weidle,<sup>1</sup> Christina L. Hutson<sup>1</sup>

Since May 2022, mpox has been identified in 108 countries without endemic disease; most cases have been in gay, bisexual, or other men who have sex with men. To determine number of missed cases, we conducted 2 studies during June–September 2022: a prospective serologic survey detecting orthopoxvirus antibodies among men in San Francisco, California, who have sex with men and a retrospective monkeypox virus PCR testing of swab specimens submitted for other infectious disease testing among

all patients across the United States. The serosurvey of 225 participants (median age 34 years) detected 18 (8.0%) who were orthopoxvirus IgG positive and 3 (1.3%) who were also orthopoxvirus IgM positive. The retrospective PCR study of 1,196 patients (median age 30 years; 54.8% male) detected 67 (5.6%) specimens positive for monkeypox virus. There are likely few undiagnosed cases of mpox in regions where sexual healthcare is accessible and patient and clinician awareness about mpox is increased.

Since May 2022, monkeypox virus (MPXV) infections have been detected in 108 countries without endemic disease. Most cases have been among gay, bisexual, or other men who have sex with men (MSM). Because lesions commonly occur on the genitals, mpox was most frequently diagnosed in clinics conducting sexually transmitted infection (STI) screening (1). The diagnosis can be challenging because the mpox rash has been confused with STIs (e.g., herpes simplex virus infection

and syphilis), hand-foot-and-mouth disease, varicella zoster virus infection, and even arthropod bites (2–4). In addition to cases being undiagnosed because of diminished clinical suspicion, some cases may have been undiagnosed if patients did not seek care (i.e., because the symptoms were mild and self-limiting or because of poor access to a medical provider). As the global outbreak continued, public health authorities continued to increase awareness of mpox. However, clinicians and public health authorities were concerned that if a high number of cases were missed, the outbreak would be difficult to control. To determine the number of undiagnosed MPXV infections in the United States, we conducted 2 studies during June–September 2022: a prospective serologic surveillance study among MSM who sought sexual health services in San Francisco, California, USA, and a retrospective study of molecular testing of specimens tested for other infectious diseases linked to specific codes from the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM), among all populations. Each study used specimens

---

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (F.S. Minhaj, M. Townsend, N. Baird, T. Navarra, L. Priyamvada, N. Wynn, W.C. Carson; S. Odafe, S.A.J. Guagliardo, E. Sims; A.K. Rao, P.S. Satheshkumar, P.J. Weidle, C.L. Hutson); HealthTrackRx, Denton, Texas, USA (V. Singh, P. Upadhyay, J. Reddy, B. Alexander); San Francisco Department of Public Health, San Francisco, California, USA (S.E. Cohen, H. Scott); University of California San Francisco and Zuckerberg San Francisco General Hospital, San Francisco (J. Szumowski); Kaiser Permanente Northern California, San Francisco (C.B. Hare)

DOI: <https://doi.org/10.3201/eid2911.230940>

<sup>1</sup>These authors contributed equally to this article.

## RESEARCH

collected during the peak of the outbreak. Our studies were reviewed by the Centers for Disease Control and Prevention (CDC) and were conducted consistent with applicable federal law and CDC policy (e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.).

## Methods

### Prospective Serologic Survey

For the primary recruitment sites for this serologic survey, we selected 3 prominent sexual health clinics (clinics A, B, C) in San Francisco that regularly treat MSM

and 1 research clinic in San Francisco (clinic D). Those 4 private and publicly funded clinics encompass an estimated 20,000 MSM patients of varying socioeconomic status, insured rates (2%–85% private, 14%–92% public, 0–40% uninsured), and races and ethnicities within the San Francisco Bay area. Patients entering the 3 sexual health clinics during June 28–August 26, 2022, were given an informational flier in English or Spanish containing a QR code that directed interested patients to a survey to self-screen for inclusion. The flier also stated that participation was voluntary and the decision to enroll would not in any way affect their medical care. Study inclusion was limited to patients who self-reported that

**Table 1.** Demographics and characteristics of 225 participants in study of prevalence of undiagnosed monkeypox virus infections during the global mpox outbreak, United States, June–September 2022\*

Characteristic or demographic	No. (%)
Demographic	
Age, y	34 (29–42)
Race/ethnicity	
Hispanic	42 (18.7)
Non-Hispanic	
Asian	35 (15.6)
Black	20 (8.9)
Native American or Pacific Islander	4 (1.8)
White	119 (52.9)
Prefer not to answer	5 (2.2)
Sexual orientation	
Bisexual	22 (9.8)
Gay	196 (87.1)
Straight	0
A different term	6 (2.7)
Prefer not to answer	1 (0.4)
Clinic	
A	23 (10.2)
B	131 (58.2)
C	52 (23.1)
D	19 (8.4)
Known contact with someone with mpox	26 (11.6)
Travel in the past 3 mo†	77 (34.2)
International	29 (43.3)
Europe	17 (25.4)
Americas	13 (19.4)
Domestic	38 (56.7)
Sex partners in the past 1 mo	
0	22 (9.8)
1–4	135 (60)
5–9	37 (16.4)
10–19	20 (8.9)
≥20	11 (4.9)
Attended a large event (e.g., festivals, parades, weddings, clubs, sex parties)	130 (57.8)
Immunocompromising conditions	
Yes	65 (28.9)
HIV	58 (89.2)
CD4 count, cells/mm <sup>3</sup>	
≥200	27 (46.6)
<200	8 (13.8)
Unknown	23 (39.7)
HIV viral load, copies/mL	
≥200	9 (15.5)
<200	34 (58.6)
Unknown	15 (25.9)

\*Results of serologic survey (Appendix 1, <https://wwwnc.cdc.gov/EID/article/29/11/23-0940-App1.pdf>).

†Location unknown for 10 persons who had traveled.

they did not have symptoms of mpox (e.g., rash, fever, lymphadenopathy), had never received an mpox diagnosis, were 18–50 years of age (the upper age limit was set to exclude childhood smallpox vaccination in the United States), and did not have a history of smallpox or mpox vaccination. Because most cases detected at that point in the outbreak were in MSM, and to ensure sufficient participation among this population at high risk for mpox, we also excluded cisgender women and persons who did not identify as ever having had male-to-male sexual contact. Participants at clinic D were recruited by a query into the electronic medical record system from HIV and HIV pre-exposure prophylaxis registries; a subset of MSM patients 18–50 years of age were sent an invitation to participate. At clinic arrival, those participants were given the same survey to self-screen. All participants who completed the self-screening questionnaire and were eligible for study inclusion, then completed a brief 7-question electronic survey that asked about factors thought to be associated with risk for mpox during the initial stage of the outbreak that could affect public health action (e.g., travel and exposure history within the past 90 days) (Appendix 1, <https://wwwnc.cdc.gov/EID/article/29/11/23-0940-App1.pdf>) (3). We collected 5 mL of blood from each participant who completed the questionnaire. Peak IgM is detected 2–3 weeks and IgG 3–5 weeks after exposure to an orthopoxvirus (including primary vaccination with ACAM2000 [second-generation live vaccinia virus vaccine] and JYNNEOS [third-generation live, non-replicating, modified vaccinia Ankara Bavarian Nordic vaccine; <https://jynneos.com>] and convalescence has been documented at 7–14 weeks after exposure. Orthopoxvirus IgM is reliably detected 4–56 days and IgG  $\geq$ 8 days after rash onset (5). Because IgG persists for several years after orthopoxvirus exposure (6), we chose IgG as the initial screening tool to detect any past orthopoxvirus exposure. To detect recent exposure, we tested positive IgG specimens for IgM. We separated serum by centrifugation, aliquoted the samples, and sent them to CDC for ELISA analysis of orthopoxvirus IgG and, if positive, IgM.

### Retrospective Molecular Testing

During the multinational outbreak that began in 2022, mpox was diagnosed by nonvariola orthopoxvirus- and MPXV-specific real-time PCR tests of lesion swab samples (7,8). Before an mpox-specific diagnosis code (B.04) was established, clinical diagnoses and testing were documented with ICD-10-CM codes representing broad symptoms of infection, which were used as a surveillance tool for early identification of potentially undiagnosed infections

**Table 2.** Clinical signs/symptoms reported by participants in study of prevalence of undiagnosed monkeypox virus infections during the global mpox outbreak, United States, June–September 2022\*

Acute illness sign/symptoms in past 3 months	No. (%)
Cough	28 (12)
Rhinorrhea	27(11)
Sore throat	23 (10)
Fever	22 (9)
Chills	21(9)
Headaches	20 (8)
Sweats	15 (6)
Malaise	15 (6)
Shortness of breath	12 (5)
Lymphadenopathy	8 (3)
Diarrhea	7 (3)
Rash	6 (3)
Wheezing	5 (2)
Itchiness	4 (2)
Nausea/vomiting	4 (2)
Abdominal pain	4 (2)
Back pain	4 (2)
Rectal bleeding	3 (1)
Stridor	2 (1)
Rectal pain	2 (1)
Eye lesions	1
Pus in stool	1
Penile discharge	1


\*Results of serologic survey (Appendix 1, <https://wwwnc.cdc.gov/EID/article/29/11/23-0940-App1.pdf>).

similar to other diseases (9,10). To evaluate the presence of MPXV within specimens received for other testing, CDC partnered with HealthTrackRx, a private laboratory that receives specimens from a variety of clinics across the United States for infectious disease testing. During June 1–September 2, 2022, CDC deidentified and tested lesion swab specimens associated with ICD-10-CM codes for genital lesions, herpes simplex virus infection, inflammation of the genital region, skin rash, and others that may overlap with symptoms of mpox (Appendix 2, <https://wwwnc.cdc.gov/EID/article/29/11/23-0940-App2.pdf>) for presence of MPXV DNA by using a clade II-specific PCR (8). After June 27, 2022, HealthTrackRx validated its own mpox clade II-specific assay (8) and continued to test specimens for MPXV that fit the ICD-10-CM codes (Appendix 2). No specimens were excluded; only basic demographic and geographic data and pertinent ICD-10-CM codes that may be associated with mpox were available from the initial test request from the submitting clinician. No information about sexual history was included.

## Results


### Prospective Serologic Survey

During the study period,  $\approx$ 8,670 patients were seen at clinics A, B, and C, of which 3,832 (44.2%) were



**Figure 1.** Total numbers and percentages of positive results for specimens tested by monkeypox virus–specific PCR under different code categories from the International Classification of Diseases, 10th Revision, Clinical Modification, United States, June–September 2022. \*Mpox add-on is defined as having an initial negative result from other testing, after which a provider requested testing for mpox.

MSM, 18–50 years of age, and may have been eligible for participation. An estimated 6,000 persons from clinic D were eligible for study participation, and 2,400 (40%) were sent an invitation to participate. A total of 398 patients started the survey. Of 358 (87.4%) participants who completed the survey, 133 were excluded for not self-identifying as having male-to-male sexual contact ( $n = 67$ ), reporting previous receipt of smallpox or mpox vaccination ( $n = 41$ ), being  $>50$  years of age ( $n = 18$ ), or reporting a past diagnosis of mpox ( $n = 7$ ). We collected serum samples from the final sample size of 225



**Figure 2.** Weekly positive detection of monkeypox virus by PCR testing and US Centers for Disease Control and Prevention case detection (<https://www.cdc.gov/ecr/index.html>), July 24–September 2, 2022. Results are from public health and select commercial laboratories and HealthTrackRx testing and US case detections. The greater number of laboratory positives than US case detections most likely results from testing of multiple samples from a single patient.

participants. Participant median age was 34 (interquartile range [IQR] 29–42) years. Most (52.9%) eligible participants were non-Hispanic White, and most (87.1%) reported sexual orientation as gay (Tables 1, 2). Twenty-six (11.6%) participants reported known contact with someone with mpox. Recent travel (previous 3 months) was reported by 77 (34.2%); among the 67 who reported a location, 38 (56.7%) had traveled in the United States, 17 (25.4%) to Europe, and 13 (19.4%) to other countries within the Americas. A total of 130 (57.8%) participants had attended a large private or public event (e.g., festivals, parades, weddings, clubs, sex parties). Most (203, 91.2%) participants had  $\geq 1$  sexual contact in the previous month, among which 68 (30.2%) had  $\geq 5$  partners. A total of 65 (28.9%) participants had an immunocompromising condition, most commonly HIV (89.2%;  $n = 58$ ). Of those who reported HIV, 8 (13.8%) reported a CD4 count  $<200$  cells/ $\text{mm}^3$  and 9 (15.5%) reported a viral load  $\geq 200$  copies/mL. Among the 47 (20.9%) who reported being ill in the previous 3 months, the most common signs/symptoms were cough, rhinorrhea, sore throat, fever, and chills (participants could report  $>1$  sign/symptom).

Of 225 serum samples tested for orthopoxvirus IgG, 18 (8.0%) were positive and 3 (1.3%) were also positive for orthopoxvirus IgM. Those 3 participants were 20–49 years of age. Two patients denied prior smallpox or mpox vaccination; vaccination status for the third patient was unknown. All 3 participants had traveled in the previous 3 months (2 internationally and 1 domestically), 1 reported attending a large event, and 1 reported having had contact with someone with mpox. All 3 participants reported having had 3–20 sex partners within the previous month. Two participants reported signs/symptoms consistent with mpox in the previous 3 months, including rash, diaphoresis, and lymphadenopathy. One participant had well-controlled HIV (CD4 count  $>200$  cells/ $\mu\text{L}$ ).

### Retrospective Molecular Testing

During the study period, MPXV testing was performed for 1,196 patients (median age 30 [IQR 19–46] years); 656 (54.8%) were men. The most common specimen collection sites were arm (24.8%;  $n = 297$ ), anogenital (18.6%;  $n = 222$ ), leg (10.1%;  $n = 121$ ), and unspecified (14.2%;  $n = 170$ ). The ICD-10-CM codes accompanying specimens were broadly categorized as disorder of the genitals, herpes-related lesions, pruritus, cellulitis, skin conditions, vaginitis, high-risk sexual behavior, mpox, miscellaneous, and not defined. A total of 67 (5.6%) specimens

**Table 3.** International Classification of Diseases, 10th Revision, Clinical Modification codes associated with PCR-positive specimens in study of monkeypox virus infections, United States, June–September 2022

Code	Description
K13.70	Disease of oral mucosa, unspecified
R36.9	Urethral discharge, unspecified
R19.8	Other specified symptoms and signs involving the digestive system and abdomen
R21, R30	Rash and other nonspecific skin eruption, pain associated with micturition
M79.10	Myalgia unspecified site
B08.8, J02.9, R21	Other specified viral infections characterized by skin and mucous membrane lesions
L98.9, N48.9	Disorder of the skin and subcutaneous tissue, unspecified, disorder of penis, unspecified
Z72.52	High-risk homosexual behavior
A63.8, A64	Other specified predominantly sexually transmitted diseases, unspecified sexually transmitted disease
R21, Z11.3	Rash and other nonspecific skin eruption, encounter for screening for infections with a predominantly sexual mode of transmission
L98.9	Disorder of the skin and subcutaneous tissue, unspecified
N48.5	Ulcer of penis
Z20.828	Contact with and (suspected) exposure to other viral communicable diseases
N50.89, R21	Other specified disorders of the male genital organs, rash and other nonspecific skin eruption
A63.0	Anogenital (venereal) warts
A60.1, A63.0	Herpes viral infection of perianal skin and rectum, anogenital (venereal) warts
L08.9	Local infection of skin and subcutaneous tissue, unspecified
N48.5, N50.89, R22.0	Ulcer of penis, other specified disorders of the male genital organs, localized swelling, mass and lump of skin and subcutaneous tissue
B34.9, R50.9, R53.83, Z20.822	Viral infection, unspecified
N48.5, R36.9, Z72.51	Ulcer of penis, urethral discharge, unspecified, high-risk heterosexual behavior
L30.8, R21	Other specified dermatitis, rash and other nonspecific skin eruption
B89, R21	Unspecified parasitic disease, rash and other nonspecific skin eruption
I88.9, N48.89, R36.9	Nonspecific lymphadenitis, unspecified, other specified disorders of penis, urethral discharge, unspecified
K60.2	Anal fissure, unspecified
N48.9, S30.812A	Disorder of penis, unspecified, abrasion of penis
N50.89	Other specified disorders of the male genital organs
L08.89, L98.8	Local infection of skin and subcutaneous tissue, unspecified, other specified disorders of the skin and subcutaneous tissue
Z11.3, Z20.822	Encounter for screening for infections with a predominantly sexual mode of transmission, contact with and (suspected) exposure to other viral communicable diseases
R07.0, R21	Pain in throat, rash and other nonspecific skin eruption
R50.9, Z20.822	Fever, unspecified, contact with and (suspected) exposure to other viral communicable diseases
Z20.2	Contact with and exposure to infections with a predominantly sexual mode of transmission
L30.8	Other specified dermatitis
B04, Z11.3	Monkeypox, encounter for screening for infections with a predominantly sexual mode of transmission
R23.8, Z20.2	Other skin changes, contact with and exposure to infections with a predominantly sexual mode of transmission
A600	Anogenital herpes viral (herpes simplex) infections
B00.2	Herpes viral gingivostomatitis and pharyngotonsillitis
N48.5, Z11.3	Ulcer of penis, encounter for screening for infections with a predominantly sexual mode of transmission
J03.90, K13.79	Acute tonsillitis, unspecified, other lesions of oral mucosa
L03.818	Cellulitis of other sites
L02.818	Cutaneous abscess of other sites

tested positive for MPXV DNA (Figure 1). The dates that the positive specimens had been obtained corresponded to the increase in mpox epidemic curve in the United States (Figure 2). Most MPXV-positive specimens were associated with skin conditions, including ICD-10-CM codes R21 (rash and other nonspecific skin eruption), L98.9 (disorder of skin and subcutaneous tissue, unspecified), L08.89 (other specified local infections of the skin and subcutaneous tissue), and disorders of the genital regions including N48.5 (ulcer of the penis) (Table 3). Among those categories, all specimens with ICD-

10-CM codes corresponding to signs/symptoms of pruritis, cellulitis, and vaginitis tested negative for MPXV; no positive specimens were from women. Among the 67 MPXV-positive specimens, 5 (7.3%) ICD-10-CM codes were classified under sexual behavior that places someone at increased STI/HIV risk and 4 (5.8%) under herpes-related lesions. Of the 67 positive specimens, 15 (20.3%) were among 74 specimens that were originally submitted for testing of other infectious organisms but after negative results had been submitted for MPXV testing at provider request.

Most specimens received were from Michigan (12.8%), Georgia (12.0%), Colorado (10.4%), and Florida (9.9%); however, the highest proportion of specimens that tested positive for mpox were from Georgia (24.5%, 35 positive), followed by Missouri (25.0%, 5 positive) and Texas (12.9%, 11 positive) (Table 4). Specimens were also tested on the STI and wound infection PCR panels at HealthTrackRx. Among the specimens testing positive for mpox, only 1 tested positive for other etiologies consistent with contamination (*Finegoldia magna*, *Cutibacterium acnes*, and *Peptostreptococcus* spp).

## Discussion

A total of 21,798 mpox cases were reported in the United States during the peak of the outbreak, June–September 2022, accounting for 72.0% of the total US cases reported as of March 2023. Despite concerns that some cases could be undetected (particularly in the MSM community), potentially preventing outbreak control, the serologic survey identified only 1.3% of MSM patients at high risk for mpox without a known mpox diagnosis who had orthopoxvirus IgM, indicating recent exposure to mpox. That rate of IgM positivity is similar to the 1.4% rate among persons experiencing homeless-

ness in San Francisco during July–October 2022 (11). Mpox was retrospectively detected by PCR in 5.6% of lesion swab samples obtained across the country, suggesting that mpox was probably undiagnosed in a small subset of symptomatic patients during the height of the mpox outbreak in the United States. The highest percentage positivity was among those who reported sexual behavior that places someone at increased for STI/HIV. However, the second highest percentage positivity was among those for whom mpox testing was retrospectively ordered by the clinician after negative diagnostic test results for other common rash illnesses, suggesting that clinician awareness was higher for mpox during this period. The data from the 2 analyses reported here indicate that as long as persons are aware of mpox and the need to seek medical care, the percentage of undiagnosed cases remains low, as it did during the peak of the outbreak.

The clinical manifestations (especially skin lesions, pustules, and rashes) of mpox patients can be confused with those of varicella zoster virus and STIs (e.g., herpes and syphilis), and mpox can co-occur with other STIs. However, in the molecular study, we did not find any significant levels of co-infections with mpox and other STIs.

**Table 4.** Positive monkeypox virus PCR detections and case detections by state, United States, June–September 2022\*

State	Total tested by HealthTrackRx	MPXV PCR positive, no. (%)	CDC case detections	Mpox cases detected by HealthTrackRx, %
Georgia	143	35 (24.5)	1,602	2.2
Missouri	20	5 (25)	72	6.9
Texas	85	11 (12.9)	2,012	0.5
Nevada	12	1 (8.3)	234	0.4
Illinois	15	1 (6.7)	1,181	0.1
California	31	2 (6.5)	4,389	0
North Carolina	18	1 (5.6)	414	0.2
Michigan	153	7 (4.6)	234	3.0
Florida	119	3 (2.5)	2,269	0.1
Colorado	124	1 (0.8)	268	0.4
Arizona	96	0	386	0
Wisconsin	95	0	74	0
Ohio	90	0	237	0
Arkansas	31	0	40	0
Oklahoma	23	0	29	0
Kentucky	16	0	40	0
Wyoming	16	0	2	0
Alabama	14	0	95	0
Indiana	14	0	195	0
Iowa	10	0	21	0
New Mexico	10	0	35	0
Oregon	10	0	191	0
Idaho	9	0	13	0
Kansas	9	0	7	0
Mississippi	8	0	51	0
Washington	7	0	469	0
Tennessee	6	0	228	0
Maryland	4	0	580	0
New Hampshire	4	0	27	0
New Jersey	2	0	614	0
Rhode Island	2	0	60	0

\*CDC, Centers for Disease Control and Prevention; MPXV, monkeypox virus.

That the earliest positive IgM result was obtained in mid-July suggests infection up to 56 days earlier. The lack of IgM detection before that time, in a small sample from 1 region, is suggestive that cases may not have been prevalent before the first detection on May 17. Of the 3 persons with an IgM-positive result, 2 self-reported symptoms consistent with mpox within the previous 3 months.

Among the limitations of our analyses, the response rates to the survey were low. The serologic survey relied on patient self-screening through the survey questionnaire, self-reported symptoms, and travel history. Also, the serologic survey was conducted in San Francisco, where infrastructure and resources may not be reflective of other geographic locations. Because the serologic survey was a point seroprevalence study, no follow-up testing or interviews were conducted among the participants who were positive for orthopoxvirus IgM; it is unknown whether any participants previously had signs/symptoms that were not reported on the survey or if signs/symptoms ultimately developed. Only 3 specimens were positive for both orthopoxvirus IgG and IgM. For the other 15 IgG-positive/IgM-negative specimens, it is unknown whether the participants had been exposed to orthopoxvirus beyond the IgM detection window or whether they did not self-report previous vaccination (many JYNNEOS vaccination campaigns were ongoing during the study period). We did not collect information on military service, which would include persons who may have received ACAM2000, a live-replicating vaccinia virus vaccine that results in production of orthopoxvirus antibodies. Because we used IgG as the initial screening tool, a participant could have been IgM positive and IgG negative; however, because that window of time is small (3–4 days), the likelihood of missing potential cases is low. The major limitations of molecular testing were similar to those of any study relying on ICD-10-CM codes for analysis and for which detailed patient history was not available beyond the ICD-10-CM codes on test requisitions.

In conclusion, the rate of undiagnosed mpox infections during the peak of reported cases in the United States was low among persons at high risk for disease (represented by participants in the San Francisco serosurvey). Mpox diagnosis was probably missed for some persons with rash (represented by retrospective molecular testing at HealthTrackRx), and providers should remain vigilant and conduct mpox testing from lesion swab samples on patients with mpox signs/symptoms. We rapidly collected our data during the peak of the outbreak

to provide information for the epidemiologic response. Ongoing serologic and molecular studies that are underway that use specimens stored before May 2022 will be useful for determining whether mpox was present before the outbreak was identified in the United States.

### Acknowledgments

We thank Inger Damon for early constructive conversations with HealthTrackRx, members of the CDC mpox outbreak response (including the Laboratory and Testing and Epidemiology Task Forces), Nathanael Gistand, staff at each participating clinic site, and the patients who volunteered for the serologic study. We also acknowledge Bernadette Aragon, Jon Oskarsson, and Judith Sansone for their research contributions.

Use of trade names and commercial sources are for identification only and do not imply endorsement by the US Department of Health and Human Services.

### About the Author

Dr. Minhaj is an emergency medicine pharmacist/toxicologist and an epidemiologist at CDC within the Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases. His work focuses on medical countermeasures related to orthopoxviruses.

### References

1. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox virus infection in humans across 16 countries. *N Engl J Med*. 2022;387:679–91. <https://doi.org/10.1056/NEJMoa2207323>
2. McCollum AM, Damon IK. Human monkeypox. *Clin Infect Dis*. 2014;58:260–7. <https://doi.org/10.1093/cid/cit703>
3. Minhaj FS, Ogale YP, Whitehill F, Schultz J, Foote M, Davidson W, et al. Monkeypox outbreak – nine states, May 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71:764–9. <https://doi.org/10.15585/mmwr.mm7123e1>
4. Hughes CM, Liu L, Davidson WB, Radford KW, Wilkins K, Monroe B, et al. A tale of two viruses: coinfections of monkeypox and varicella zoster virus in the Democratic Republic of Congo. *Am J Trop Med Hyg*. 2020;104:604–11. <https://doi.org/10.4269/ajtmh.20-0589>
5. Karem KL, Reynolds M, Braden Z, Lou G, Bernard N, Patton J, et al. Characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. *Clin Diagn Lab Immunol*. 2005;12:867–72. <https://doi.org/10.1128/CDLI.12.7.867-872.2005>
6. Taub DD, Ershler WB, Janowski M, Artz A, Key ML, McKelvey J, et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. *Am J Med*. 2008;121:1058–64. <https://doi.org/10.1016/j.amjmed.2008.08.019>


7. Li Y, Olson VA, Laue T, Laker MT, Damon IK. Detection of monkeypox virus with real-time PCR assays. *J Clin Virol*. 2006;36:194–203. <https://doi.org/10.1016/j.jcv.2006.03.012>
8. Li Y, Zhao H, Wilkins K, Hughes C, Damon IK. Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA. *J Virol Methods*. 2010;169:223–7. <https://doi.org/10.1016/j.jviromet.20107.012>
9. Dixon BE, Rahurkar S, Ho Y, Arno JN. Reliability of administrative data to identify sexually transmitted infections for population health: a systematic review. *BMJ Health Care Inform*. 2019;26. <https://doi.org/10.1136/bmjhci-2019-100074>
10. Mauk KC, Torrione EA, Flagg EW. Can diagnostic codes in health care claims data identify confirmed chlamydial and gonococcal infections? A retrospective cohort study, 2003 to 2017. *Sex Transm Dis*. 2021;48:S26–s31. <https://doi.org/10.1097/OLQ.0000000000001454>
11. Waddell CJ, Filardo TD, Prasad N, Pellegrini GJ Jr., Persad N, Carson WC, et al. Possible undetected mpox infection among persons accessing homeless services and staying in encampments—San Francisco, California. *MMWR Morb Mortal Wkly Rep*. 2023;72:227–31. <https://doi.org/10.15585/mmwr.mm7209a3>

Address for correspondence: Faisal S. Minhaj, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop H24-12, Atlanta, GA 30329-4027, USA; email: rhu5@cdc.gov

May 2023

## Bacterial Infections

- Trends in and Risk Factors for Recurrent *Clostridioides difficile* Infection, New Haven County, Connecticut, USA, 2015–2020
- Phylogenetic Analysis of Transmission Dynamics of Dengue in Large and Small Population Centers, Northern Ecuador
- Emergence of Erythromycin-Resistant Invasive Group A *Streptococcus*, West Virginia, USA, 2020–2021
- Environmental, Occupational, and Demographic Risk Factors for Clinical Scrub Typhus, Bhutan
- Misdiagnosis of *Clostridioides difficile* Infections by Standard-of-Care Specimen Collection and Testing among Hospitalized Adults, Louisville, Kentucky, USA, 2019–2020
- SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021
- Disparities in Implementing COVID-19 Prevention Strategies in Public Schools, United States, 2021–22 School Year
- *Leishmania donovani* Transmission Cycle Associated with Human Infection, *Phlebotomus alexandri* Sand Flies, and Hare Blood Meals, Israel
- Case–Control Study of Long COVID, Sapporo, Japan
- Influence of Sex and Sex-Based Disparities on Prevalent Tuberculosis, Vietnam, 2017–2018 [
- Use of High-Resolution Geospatial and Genomic Data to Characterize Recent Tuberculosis Transmission, Botswana



- *Borrelia miyamotoi* Infection in Immunocompromised Man, California, USA, 2021
- Novel Circovirus in Blood from Intravenous Drug Users, Yunnan, China
- Cystic Echinococcosis in Northern New Hampshire, USA
- Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
- Mpox among Public Festival Attendees, Chicago, Illinois, USA, July–August 2022
- Severe *Streptococcus equi* Subspecies *zooepidemicus* Outbreak from Unpasteurized Dairy Product Consumption, Italy
- Characteristics and Treatment of *Gordonia* spp. Bacteremia, France
- No Substantial Histopathologic Changes in *Mops condylurus* Bats Naturally Infected with Bombali Virus, Kenya
- Comparative Aerosol and Surface Stability of SARS-CoV-2 Variants of Concern
- Poor Prognosis for Puumala Virus Infections Predicted by Lymphopenia and Dyspnea
- Rustrela Virus as Putative Cause of Nonsuppurative Meningoencephalitis in Lions
- Limited Nosocomial Transmission of Drug-Resistant Tuberculosis, Moldova
- *Burkholderia pseudomallei* Laboratory Exposure, Arizona, USA
- Epizootic Hemorrhagic Disease Virus Serotype 8, Italy, 2022
- Spatiotemporal Evolution of SARS-CoV-2 Alpha and Delta Variants during Large Nationwide Outbreak of COVID-19, Vietnam, 2021
- Emerging Invasive Group A *Streptococcus* M1UK Lineage Detected by Allele-Specific PCR, England, 2020
- Cutaneous Leishmaniasis Caused by *Leishmania infantum*, Israel, 2018–2021
- Fatal Case of Heartland Virus Disease Acquired in the Mid-Atlantic Region, United States
- Case Report and Literature Review of Occupational Transmission of Monkeypox Virus to Healthcare Workers, South Korea
- Unknown Circovirus in Immunosuppressed Patient with Hepatitis, France, 2022

**EMERGING  
INFECTIOUS DISEASES**

To revisit the May 2023 issue, go to:

<https://wwwnc.cdc.gov/eid/articles/issue/29/5/table-of-contents>



*EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.*

# Prevalence of Undiagnosed Monkeypox Virus Infections during Global Mpox Outbreak, United States, June–September 2022

## Appendix 1

### Questionnaire

The following pages show the 7-question electronic survey given to study participants at clinic D who were recruited by a query into the electronic medical record system from HIV and HIV pre-exposure prophylaxis registries. A subset of MSM patients 18–50 years of age were sent an invitation to participate and completed the questionnaire.

# Serosurvey

Thank you for your willingness to participate in this evaluation. We will ask you a few questions (< 5 mins) about your activities in the past 3 months. We will ask to look at your arms to see if there is a smallpox vaccine scar and ask for your age. Also, we will take a blood sample of 5 ml (about one teaspoon) from you. We will test your blood to see if you have been exposed to the Orthopoxvirus, Monkeypox virus. We will use an assay to detect the presence of anti-Orthopoxvirus antibodies.

This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.§

§ See e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.

---

Would you like to complete this survey in Spanish or English?

- English/inglés  
 Spanish/español

¿Quiere completar esta encuesta en español o inglés?

---

Por favor, siga este enlace para acceder a la encuesta en español: [haga clic aquí](#)

**Demographics**

Have you previously participated in this study?  Yes  No

In which clinic are you taking this survey?  San Francisco City Clinic  San Francisco AIDS Foundation (Strut)  Ward 86  Kaiser  Other

You mentioned you are located in another clinic, can you please specify? \_\_\_\_\_

Participant number \_\_\_\_\_

Are you older than 50 years old?  Yes  No

What is your age? \_\_\_\_\_

What was your sex assigned at birth?  Female  Male  Prefer not to answer

Do you currently describe yourself as male, female, or transgender?  Female  Male  Transgender female  Transgender male  Another gender identity  Prefer not to answer

You mentioned you prefer another gender identity, can you specify? \_\_\_\_\_

Which of the following best represents how you think of yourself?  Lesbian or gay  Straight (not gay or lesbian)  Bisexual  A different term  Prefer not to answer

You mentioned you prefer a different term, can you specify? \_\_\_\_\_

What is your race?  American Indian or Alaska Native  Asian  Black or African American  Native Hawaiian or Other Pacific Islander  White  Other  Declined to answer  Unknown

Please specify 'Other' race. \_\_\_\_\_

---

What is your ethnicity?

- Hispanic or Latino
- Non-Hispanic or Latino
- Other
- Declined to answer
- Unknown

---

Please specify 'Other' ethnicity.

\_\_\_\_\_

---

Have you ever had any male-to-male sexual contact?  
This includes: genital touching, oral-penile (e.g. gave or received a blowjob), oral-anal (e.g. rimming), and/or penile-anal sex (e.g. insertive or receptive sex as a top, bottom or versatile).

- Yes
- No

**Health Information**

Survey 25% Complete

Have you previously been vaccinated for smallpox or monkeypox?  Yes  No  Unknown

Which smallpox vaccine did you receive?  Dryvax (discontinued in 2008)  ACAM2000 (started in 2008)  JYNNEOS (started in 2022)  Unknown

Have you previously received a monkeypox diagnosis?  Yes  No

In the past 3 months, have you been sick with something other than a chronic illness?  Yes  No

You mentioned you may have been sick in the past 3 months, what symptoms did you have?  Rash  Fever  Chills  Sweats  General feeling of illness/weakness  Muscle aches  Itchiness  Headache  Eye lesions  Red or swollen eyes  Runny nose  Wheeze  Cough  Shortness of breath  Difficulty breathing in, with high pitched wheezy sound  Swollen glands  Sore throat  Diarrhea  Nausea/Vomiting  Abdominal pain  Back pain  Urgency to defecate  Rectal pain  Rectal bleeding  Pus/blood on stool  Other symptoms (specify)

Please specify other symptoms: \_\_\_\_\_

When did these symptoms start? \_\_\_\_\_

WARNING: The date entered is more than 3 months ago!

WARNING: The date entered is a future date!

Are you currently sick with something other than a chronic illness?  Yes  No

---

Close personal contact includes contact with:

Any person presenting similar symptoms OR A known confirmed case OR Material (body fluids, objects, bedding, etc.) that came in contact with a case or a person with similar symptoms

---

Close intimate contact includes:

Hugging, cuddling, kissing, massaging, other skin-to-skin contact OR Oral, anal, and vaginal sex or touching the genitals (penis, testicles, labia, and vagina) or anus (butt) of another person OR Touching fabrics or objects during sex that were used by another person that have not been disinfected, such as bedding, towels, fetish gear, and sex toys

---

Have you been in close personal and/or intimate contact with anyone who has received a monkeypox diagnosis?  Yes  No

---

In the past 1 month, how many unique sexual partners have you had? (Sexual partners refers to partners for oral, anal, or vaginal sex.) Please provide your best estimate if you do not know an exact number. \_\_\_\_\_

---

Do you have any known immunocompromising conditions or take immunosuppressive medications? Immunocompromising conditions can include diseases like HIV/AIDS, diabetes, lupus, organ transplants, stem cell transplants, and cancer. Certain medicines like chemotherapy, biologic therapies, and steroids can also weaken the immune system.  Yes - HIV  Yes - a condition that's not HIV  No

---

What is your CD4 count, if known?  ≥200  < 200  Unknown

---

What is your viral load, if known?  ≥200  < 200 or undetectable  Unknown

---

You mentioned that you have an immunocompromising condition or treatment, please describe the associated condition or treatment. \_\_\_\_\_

---

Date of serum sample \_\_\_\_\_  
(@TODAY)

---

**Travel**

Survey 50% Complete

Did you travel within the past 3 months out of the state or country?

- Yes
- No

Trip 1: Where did you travel (city, state, country)

\_\_\_\_\_

Trip 1: When did you leave?

\_\_\_\_\_

Trip 1: When did you return?

\_\_\_\_\_

The return date of your trip is before the leave date of your trip

WARNING: The date entered is a future date!

WARNING: The date entered is more than 3 months ago!

Was there another trip?

- Yes
- No

Trip 2: Where did you travel (city, state, country)

\_\_\_\_\_

Trip 2: When did you leave?

\_\_\_\_\_

Trip 2: When did you return?

\_\_\_\_\_

The return date of your trip is before the leave date of your trip

WARNING: The date entered is a future date!

WARNING: The date entered is more than 3 months ago!

Was there another trip?

- Yes
- No

Trip 3: Where did you travel (city, state, country)

\_\_\_\_\_

Trip 3: When did you leave?

\_\_\_\_\_

Trip 3: When did you return?

\_\_\_\_\_

The return date of your trip is before the leave date of your trip

WARNING: The date entered is a future date!

---

WARNING: The date entered is more than 3 months ago!

---

Was there another trip?

- Yes
- No

---

Trip 4: Where did you travel (city, state, country)

---

---

Trip 4: When did you leave?

---

---

Trip 4: When did you return?

---

---

The return date of your trip is before the leave date of your trip

---

WARNING: The date entered is a future date!

---

WARNING: The date entered is more than 3 months ago!



**Events**

Survey 75% Complete

In the past 3 months, have you attended any large public or private events (e.g., festivals, parades, weddings, clubs, sex parties)?

- Yes
- No

What was the name of this event?

\_\_\_\_\_

When did this event take place?

\_\_\_\_\_

WARNING: The date entered is a future date!

WARNING: The date entered is more than 3 months ago!

Where did this event take place (city, state, country)?

\_\_\_\_\_

Was there another event?

- Yes
- No

What was the name of this event?

\_\_\_\_\_

When did this event take place?

\_\_\_\_\_

WARNING: The date entered is a future date!

WARNING: The date entered is more than 3 months ago!

Where did this event take place (city, state, country)?

\_\_\_\_\_

Was there another event?

- Yes
- No

What was the name of this event?

\_\_\_\_\_

When did this event take place?

\_\_\_\_\_

WARNING: The date entered is a future date!

WARNING: The date entered is more than 3 months ago!

Where did this event take place (city, state, country)?

\_\_\_\_\_

*EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.*

# Prevalence of Undiagnosed Monkeypox Virus Infections during Global Mpox Outbreak, United States, June–September 2022

## Appendix 2

**Appendix Table.** ICD-10-CM codes with possible symptom and risk factor overlap with mpox.

ICD Code	Concept name
A51.0	Primary genital syphilis
A53.9	Syphilis unspecified
B00	Herpesviral (herpes simplex) infections
B00.9	Herpesviral infection unspecified
B02	Herpes zoster
L98.9	Disorder of skin and subcutaneous tissue, unspecified
L08.89	Other specified local infections of the skin and subcutaneous tissue
N00-N99	Diseases of genitourinary system (nonspecific)
N48.5	Ulcer of the penis
N48.89	Other specified disorders of the penis
N50.9	Disorder of male genital organs unspecified
N76.5	Ulceration of vagina
N76.6	Ulceration of vulva
N89.9	Noninflammatory disorder of vagina unspecified
N90	Other noninflammatory disorders of vulva and perineum
N90.89	Other spec noninflammatory disorder of the vulva and perineum
N90.9	Noninflammatory disorder vulva and perineum unspecified
R21.0	Rash and other nonspecific skin eruption
R23.8	Other skin changes
Z72.51	High-risk heterosexual behavior
Z72.52	High-risk homosexual behavior
Z75.52	High risk bisexual behavior